26 completed, 14 active not recruiting, 7 recruiting, 4 terminated. 34 Phase 2, 27 Phase 1, 5 Phase 3.
Follow ipatasertib: new trials by email Literature Review of ipatasertib trials Research Report on ipatasertib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial Biopsy Procedure, Biospecimen Collection, Computed Tomography - Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 33 | 2023-09-22 | 2026-08-24 |
| Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE) Atezolizumab 1200 mg in 20 ML Injection, Inavolisib, Ipatasertib - Early-stage Breast Cancer | Phase 2 | Recruiting | German Cancer Research Center | 240 | 2023-06-29 | 2025-03-20 |
| A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study Ipatasertib, Tiragolumab, Atezolizumab - Cancer | Phase 3 | Recruiting | Hoffmann-La Roche | 100 | 2023-06-01 | 2026-10-02 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial Alpelisib, Binimetinib, Biopsy Procedure - Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 2900 | 2023-04-07 | 2026-10-15 |
| Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers Biospecimen Collection, Computed Tomography, Ipatasertib - FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 96 | 2023-03-31 | 2026-10-01 |
| Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression Ipatasertib 300mg, Fulvestrant 500g, Palbociclib 75mg-125mg - Metastatic Breast Cancer, ER+ Breast Cancer | Phase 2 | Active not recruiting | Royal Marsden NHS Foundation Trust | 57 | 2022-12-28 | 2026-04-14 |
| Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer Biopsy Procedure, Biospecimen Collection, Cisplatin - Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 1 | Recruiting | National Cancer Institute (NCI) | 46 | 2022-09-19 | 2026-09-22 |
| Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer Biopsy Procedure, Carboplatin, Ipatasertib - Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 25 | 2022-09-08 | 2026-09-22 |
| Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck Biopsy Procedure, Biospecimen Collection, Computed Tomography - Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 52 | 2022-07-26 | 2026-09-21 |
| A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer Atezolizumab - 28 Day Cycle, Bevacizumab, Ipatasertib - Endometrial Cancer | Phase 1 / Phase 2 | Recruiting | Alliance Foundation Trials, LLC. | 148 | 2021-10-20 | 2026-04-01 |
| CRAFT: The NCT-PMO-1602 Phase II Trial Vemurafenib, Cobimetinib, Atezolizumab - Metastatic or Locally Advanced Malignancies | Phase 2 | Completed | German Cancer Research Center | 72 | 2021-10-13 | 2025-01-08 |
| A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors Ipatasertib, Cobimetinib, Trastuzumab Emtansine - Ovarian Cancer | Phase 2 | Active not recruiting | Hoffmann-La Roche | 176 | 2021-10-07 | 2026-09-10 |
| Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy Ipatasertib - NSCLC Stage IV, NSCLC Stage IIIB | Phase 2 | Unknown | Jun Zhang, MD, PhD | 60 | 2021-09-14 | 2023-11-07 |
| Neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men With Localized, High Risk Prostate Cancer Ipatasertib, Darolutamide, Androgen Deprivation Therapy - Castrate Resistant Prostate Cancer | Phase 1 / Phase 2 | Terminated | David VanderWeele | 6 | 2021-07-13 | 2023-11-13 |
| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer Giredestrant, Abemaciclib, Ipatasertib - Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer | Phase 1 / Phase 2 | Recruiting | Hoffmann-La Roche | 316 | 2021-06-22 | 2026-10-06 |
| Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST) Atezolizumab + Ipatasertib, Atezolizumab + Bevacizumab - Gastric Adenocarcinoma, Metastatic Gastric Cancer | Phase 2 | Completed | Hospices Civils de Lyon | 54 | 2021-03-19 | 2026-06-09 |
| Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor Ipatasertib, Fulvestrant, Placebo - Breast Cancer | Phase 3 | Active not recruiting | Canadian Cancer Trials Group | 250 | 2021-01-27 | 2026-04-13 |
| Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study Entrectinib, Alectinib, Atezolizumab - Solid Tumors | Phase 2 | Active not recruiting | Hoffmann-La Roche | 920 | 2021-01-18 | 2026-09-04 |
| A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response Entrectinib, Inavolisib, Alectinib - Advanced Unresectable or Metastatic Solid Malignancy | Phase 2 | Completed | Genentech, Inc. | 252 | 2021-01-13 | 2025-01-08 |
| A Study Of The Pharmacokinetics And Safety Of Ipatasertib In Chinese Participants With Locally Advanced Or Metastatic Solid Tumors. Ipatasertib - Solid Tumors | Phase 1 | Completed | Hoffmann-La Roche | 12 | 2020-11-03 | 2023-05-08 |
Showing 20 of 55. Sign in to see all of them.
Breast Neoplasms (17) · Ovarian Neoplasms (6) · Prostatic Neoplasms (6) · Neoplasms (5) · Neoplasm Metastasis (4) · Triple Negative Breast Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (3) · Endometrial Neoplasms (3) · Stomach Neoplasms (3) · Carcinoma (2) · Fallopian Tube Neoplasms (2) · Glioblastoma (2) · Hypopharyngeal Neoplasms (2) · Laryngeal Neoplasms (2) · Lymphoma (2)
Hoffmann-La Roche (17) · Genentech, Inc. (11) · National Cancer Institute (NCI) (8) · Canadian Cancer Trials Group (2) · German Cancer Research Center (2) · Queen Mary University of London (2) · Alliance Foundation Trials, LLC. (1) · City of Hope Medical Center (1) · David VanderWeele (1) · Fondazione per la Medicina Personalizzata (1) · Hospices Civils de Lyon (1) · Icahn School of Medicine at Mount Sinai (1) · Institute of Cancer Research, United Kingdom (1) · Jun Zhang, MD, PhD (1) · Massachusetts General Hospital (1)
United States (38) · Spain (23) · United Kingdom (19) · France (16) · South Korea (15) · Australia (13) · Italy (13) · Canada (10) · Germany (9) · Israel (8) · Taiwan (8) · Belgium (7) · Japan (7) · Poland (7) · Brazil (6)
Peter Schmid (2) · Aaron Hansen (1) · Alicia Okines (1) · Amy Tiersten, MD (1) · Andrea Botticelli (1) · Andreas Schneeweiss, Prof. Dr. (1) · Antonio Llombart, MD (1) · Daniel Maslyar, M.D. (1) · David VanderWeele, MD\Phd (1) · Jacob S Thomas (1) · James M Ford (1) · Jann Lee, PhD (1) · Joanne Mortimer (1)
PMID 34471960, PMID 25009010, PMID 26586415, PMID 27872130, PMID 28800861, PMID 30592991, PMID 31147675, PMID 32203306, PMID 32205017, PMID 32463741, PMID 32737717, PMID 33048619, PMID 34246347, PMID 34808524, PMID 34860318, PMID 35133871, PMID 35138919, PMID 36305957, PMID 36351402, PMID 36697317, PMID 37023705, PMID 37053535, PMID 37322121, PMID 37339186, PMID 37934000, PMID 38060199, PMID 38591867, PMID 39096924, PMID 39666929, PMID 39693587, PMID 39721851, PMID 39913886, PMID 40022843, PMID 40086048, PMID 40770648, PMID 40865033, PMID 40896848, PMID 41023484, PMID 41066729, PMID 41213248, PMID 41392942, PMID 41963505, PMID 42061370, PMID 42691436
2017 (6), 2019 (4), 2023 (4), 2018 (3), U10CA180820 (3), 2014 (2), 2016 (2), U10CA180868 (2), 2009 (1), U10CA180888 (1), U24CA196172 (1), UM1CA186644 (1), UM1CA186717 (1)